Release Date: 06/05/13 13:19 Summary: Q1 2013 net profit of $123 million, reaffirms guidance Price Sensitive: Yes Download Document 89.64KB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%